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Abstract
PLEX-ID uses polymerase chain reaction-electrospray ionization/mass spectrometry for rapid identification of infectious agents in clinical
samples. We evaluated its concordance with our centre’s standard methods (SM) for bacterial and fungal detection in bronchoalveolar
lavage (BAL) fluid in a prospective observational cohort study. The primary outcome was concordance (%) between SM and PLEX-ID.
Secondary outcomes included concordance when excluding commensal oral flora, detection of resistance genes, and PLEX-ID’s potential
impact on clinical management, as determined by two independent reviewers. Included were 101 specimens from 94 patients. BALs were
performed primarily for suspected pneumonia (76/101, 75%) and lung transplant work-ups (12/101, 12%). Most specimens yielded at least
one organism by either method (92/101, 91%). Among all microorganisms detected (n = 218), 83% and 17% were bacterial and fungal,
respectively. Overall concordance between SM and PLEX-ID was 45% (45/101). Concordance increased to 66% (67/101) when discordance
for commensal flora was excluded. PLEX-ID failed to detect 21% of all 183 SM-identified organisms, while SM did not identify 28% of the 191
PLEX-ID-identified organisms (p <0.001). There was low concordance for mecA detection. Two infectious-disease specialists’ analyses
concluded that in most of the 31 discordant, non-commensal cases, PLEX-ID results would have had little or no impact on patient
management; in eight cases, however, PLEX-ID would have led to ‘wrong decision-making’. The tested version of PLEX-ID concurred
weakly with standard methods in the detection of bacteria and fungi in BAL specimens, and is not likely to be useful as a standalone tool for
microbiological diagnosis in suspected respiratory infections.
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Introduction
Definitive identification of pathogens causing lower respiratory
tract infections (LRTIs) requires time and specialized labora-
tory personnel. In the days preceding microbiological diagno-
sis, patients often receive broad-spectrum antimicrobials that
may nonetheless be ineffective. Molecular diagnostic tools such
as polymerase chain reaction (PCR) have increased sensitivity
and reduced turnaround time, but even multiplex PCR remains
only partially broad-range, as it requires anticipation of specific
pathogens for their detection [1].
Currently research-use-only (RUO), the Abbott PLEX-ID
system is a platform for pathogen detection combining
broad-range PCR with electrospray ionization-mass spec-
trometry (PCR/ESI-MS). Minute quantities of deoxyribonu-
cleic acid (DNA) are extracted from clinical specimens and
amplified via PCR [2]. Amplicons undergo ESI-MS, allowing
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE INFECTIOUS DISEASES
for the determination of their base composition. Computer-
ized triangulation employs an internal database containing
listings of base compositions with linking orders for known
microbes to determine pathogens’ genotypic identity.
PLEX-ID remains experimental and requires validation in
the clinic. A recent retrospective study comparing PLEX-ID
with standard blood-culturing techniques in blood-borne
bacterial and yeast infections yielded concordances of 98.7%
and 96.6% at genus and species levels, respectively [3]. For
pure yeast detection, Simner et al. [4] reported a concordance
of 91.8% between traditional culture and PLEX-ID’s broad
fungal assay in formalin-fixed, paraffin-embedded tissue sam-
ples, some of which were more than a decade old. The
PLEX-ID/flu assay [5] was tested against nasopharyngeal
specimens positive by PCR for the influenza virus and
concurred at 91.3% and 95.3% for influenza A and B,
respectively [6].
Prospective studies across a wider variety of clinical
specimens are lacking, however. In this proof-of-concept study,
our objectives were to quantify PLEX-ID’s concordance with
our centre’s standard methods (SM) for bacterial and fungal
detection in the bronchoalveolar lavage (BAL) fluid of patients
undergoing bronchoscopy, and qualitatively evaluate the clinical
consequences of PLEX-ID results in discordant cases.
Materials and Methods
Study design, patients and samples
This prospective, single-centre observational cohort study
included all consecutive BAL specimens from any in- or
outpatients undergoing clinically indicated bronchoscopy and
with at least 5 mL of fluid remaining after extraction for the
SM, collected between 1 January and 1 September 2013 at the
Geneva University Hospitals, an 1800-bed tertiary-care med-
ical centre. No more than two samples from the same patient
were included. Immediately after sterile extraction of BAL fluid
for SM processing, samples were stored at 80°C for later
batch-testing via PLEX-ID.
Ethics
The study protocol and related materials were approved by
the University of Geneva’s ethics committee (reference n°
12-265); the study was carried out in accordance with the
Declaration of Helsinki, 6th revision. A waiver of informed
consent was granted given the study’s observational nature.
Outcomes
The primary outcome was concordance (%) between SM and
PLEX-ID for bacteria and fungi at genus and species levels.
Secondary outcomes included concordance (i) beyond
non-commensal oral flora, as SM do not typically identify all
oral flora at the species and/or genus level (see below), (ii) for
genus identification, and (iii) for detection of resistance genes
mecA, vanA, vanB and KPC (although the latter three genes have
rarely been detected at our institution). Finally, (iv) PLEX-ID’s
potential impact on therapeutic decision-making for discordant
non-commensal specimens was qualitatively assessed via a
clinical analysis undertaken independently by two infec-
tious-disease specialists.
Definitions
Immunosuppression. In accordance with the Centers for Dis-
ease Control and Prevention’s definition [7], patients were
considered immunosuppressed if they had one or more of the
following: neutropenia (absolute neutrophil count <500/mm3),
leukaemia, lymphoma, human immunodeficiency virus (HIV)
with CD4 count <200/lL or early post-transplant state
(<6 months), or were receiving cytotoxic chemotherapy or
high-dose steroids.
Lower respiratory tract infection. Lower respiratory tract infec-
tion was defined, per European guidelines, as pneumonia and/
or an acute illness present for 21 days or less, usually with
cough as the main symptom, with at least one other lower
respiratory-tract symptom (sputum production, dyspnoea,
wheeze or chest discomfort/pain) and no alternative explana-
tion (e.g. sinusitis or asthma) [8].
Standard methods
Our centre’s standard diagnostic methods for BAL analysis
include direct microscopic specimen examination with Gram,
acridine orange and calcofluor white staining, and bacterial and
fungal cultures, as well as Mycoplasma and Chlamydia-specific
PCR. Bacterial and fungal cultures are performed by streaking
a calibrated loop on various generic and selective media [9];
buffered charcoal yeast agar is routinely employed for the
detection of Legionella spp. Colonies are quantitatively
reported (e.g. >103 cfu/mL) and identified using a combination
of manual (e.g. optochin, pneumo-agglutination) and molecular
assays (matrix-assisted laser desorption/ionization-time of
flight mass spectrometry (MALDI-TOF), Bruker MALDI Bio-
Typer 2.0, Billerica, MA, USA). Fungi are identified by
morphology when grown on specific media as well as by
MALDI-TOF (after extraction, using the commercially available
Bruker database), and by 18S and/or internal transcribed
spacer (ITS) gene sequencing when discordant.
Upon request, specific PCRs are performed for the
detection of Pneumocystis jirovecii, other fungi, mycobacteria
(using GeneXpert; Cepheid, Sunnyvale, CA, USA), and a
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panel of respiratory viruses (adenovirus, coronaviruses, human
metapneumovirus, influenza A and B, parainfluenza viruses,
picornaviruses and respiratory syncytial virus). PCR detection
is considered positive for both P. jirovecii and viruses if the
cycling threshold (CT) value is ≤39.
By SM, the identification of commensal oral flora in culture
is often not performed at the species level. An optochin test is
used to identify the presence of Streptococcus pneumoniae
among oral streptococci. Other bacteria are identified by
MALDI-TOF MS. When only commensal oral bacteria are
identified (e.g. Neisseria flavus and Micrococcus spp.), the result
returned by the laboratory is ‘oral flora’ with quantification.
PLEX-ID analysis
For both bacterial (including resistance genes coding for mecA,
vanA, vanB, vanC and KPC) and fungal analyses, nucleic acids
were extracted from 1 mL of BAL native fluid and recovered
in 280 lL using a magnetic-bead-based method with the
PLEX-ID SP instrument (extractor) and the PLEX-ID FH
instrument (fluid handler) provided in PLEX-ID’s Ultrapure
DNA Prep Kit (from Abbott Molecular; not commercially
available). For each sample, 15 lL of nucleic acids were
distributed using the PLEX-ID FH into 16 reaction wells of
96-well assay plates. Amplification was performed with either
the PLEX-ID Bac Spectrum SF Assay or the PLEX-ID Fungal
Spectrum Assay amplification reagent kits (Abbott Molecular,
Des Plaines, IL, USA), which were designed to detect a
spectrum of more than 800 bacterial and fungal nucleic acids.
Electrospray ionization and MS identified the base compo-
sitions of the amplicons; their linking order was determined via
bioinformatic triangulation using an internal database. Of note,
the tested PLEX-ID assay was devised to detect pathogens in
sterile fluids only; it was not designed for use in BAL pathogen
detection.
Determining concordance for oral flora. As described above, SM
allow for identification of commensal oral flora on a broad
taxonomic level; PLEX-ID is by definition a genotypic diagnos-
tic tool. We attempted to mitigate this inequality by prospec-
tively deeming PLEX-ID results concordant with the
laboratory designation ‘oral flora’ whenever PLEX-ID identi-
fied any organism on our centre’s list of commensal oral flora
(Appendix S1).
Analysis of PLEX-ID’s potential impact on clinical
decision-making
Two infectious-disease specialists not previously involved in
the study (SE and SH) were asked to independently review
PLEX-ID’s potential clinical impact in cases of discordant,
non-commensal specimens. The physicians first reviewed
patients’ clinical charts, which included all data on the clinical
course, including the results of BAL analysis by SM. PLEX-ID
results were then revealed. The physicians were asked four
questions, to be answered via Likert items (Fig. 1).
Statistical analysis
Descriptive analyses were performed within Stata, Release 12
(StataCorp, College Station, TX, USA). All tests were
two-sided at the 0.05 significance level. Rates of SM and
PLEX-ID positivity and concordance were compared using
chi-squared tests. Logistic regression models were con-
structed to evaluate potential associations between specimen
and patient characteristics and concordance between PLEX-ID
and SM. The clinical analysis was assessed for inter-rater
reliability by means of inter-rater agreement percentages and
Cohen’s kappa index.
Results
Patient characteristics
There were 101 consecutive BAL specimens from 94 patients
included during the study period (Table 1). Patients’ median
age was 54 years (range, 1–89 years); 49 (52%) were male and
36 (38%) were immunosuppressed. Among the latter, 14/36
(38%) were lung-transplant recipients (LTR). Twenty-three
patients (24%) were intubated at the time of their bronchos-
copy. Patients underwent bronchoscopy primarily for pre-
sumed pneumonia (76/101, 75%), routine transplant work-ups
(12/101, 12%) and malignancy work-ups (5/101, 5%). Most (59/
101, 58%) post-bronchoscopy diagnoses were not infection
related and included interstitial pneumopathies and transplant
rejection. Pneumonia was diagnosed in 41/101 (41%); among
these, 71%, 7% and 7% were considered to be bacterial, viral
and tuberculous, respectively, while 10% were attributed to
P. jirovecii; only two cases (5%) of non-Pneumocystis fungal
pneumonia were diagnosed.
Sample characteristics
Positivity rate and microorganism taxonomy. As shown in Table 1,
most BAL specimens yielded evidence of at least one organism
by either SM or PLEX-ID (92/101, 91%); the median number of
microorganisms per specimen was two (range, 0–7). Among all
microorganisms detected (n = 218), 83% and 17% were
bacterial and fungal, respectively. Among fungi, 26/36 (72%)
were yeasts. In all, 56 distinct bacterial and fungal species were
identified, 52 by SM and 46 by PLEX-ID. Viral panels were
performed on 56/101 (55%) samples; of these, seven were
positive (two yielding influenza B, two a picornavirus, one an
adenovirus, one a parainfluenza virus and one a metapneumo-
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virus). The picornaviruses and adenovirus were not consid-
ered causative; in all other cases the post-bronchoscopy
diagnosis was viral pneumonia. PLEX-ID did not analyse viral
pathogens.
Concordance
Overall concordance between SM and PLEX-ID was 45%
(Table 2). Compared with all SM as a reference standard,
sensitivity and specificity of PLEX-ID were, respectively, 59%
(95% CI, 48–70%) and 21% (95% CI, 15–28%); positive and
negative predictive values were, respectively, 30% (95% CI, 23–
37%) and 48% (95% CI, 35–61%). In a subgroup of specimens
(n = 41) from 40 patients with a post-bronchoscopy diagnosis
of pneumonia, overall concordance between SM and PLEX-ID
was 30% (12/41). Table 3 lists the organisms identified by
either or both methods in this subgroup.
Among all specimens, concordance increased to 66% (67/
101) when discordance for commensal oral flora was
excluded. In the subgroup of specimens from patients with a
post-bronchoscopy diagnosis of pneumonia, concordance
increased to 54% (22/41) when discordance for commensal
flora was excluded.
Among discordant non-commensal specimens, the rule was
complete discordance: only two samples concurred on genus
but not species identification. Among specimens with no
commensal organisms, PLEX-ID sensitivity increased to 65%
(95% CI, 52–76%), while specificity declined slightly to 18%
(95% CI, 7–35%); positive predictive value increased to 62%
FIG. 1. Hypothetical questions asked for
clinical management analysis.
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(95% CI, 50–73%) and negative predictive value decreased to
20% (95% CI, 8–39%).
PLEX-ID failed to detect 21% of the 183 SM-identified
organisms, while SM did not recover 28% of the 191
PLEX-ID-identified organisms (p <0.001); this pattern held
when excluding commensal bacteria (24/68 (35%) vs. 26/70
(37%), respectively). Organisms most often missed by PLEX-ID
were P. jirovecii (missed in 5/7 (71%)), Actinomyces odontolyticus
(4/18, 22%) and Haemophilus influenzae (2/7, 29%). Conversely,
SM most often missed Candida albicans (8/16, 50%), Strepto-
coccus spp. (5/15, 33%) and S. pneumoniae (5/6, 83%) when
these were detected by PLEX-ID. PLEX-ID detected fungal
organisms significantly more frequently than SM (42% vs. 17%,
p 0.030). The only resistance gene detected by either method
was mecA. PLEX-ID identified mecA in seven specimens; SM
concurred in only two of these, despite the use of a
mecA-specific PCR performed on every suspect colony.
Possible predictors for discordance. Univariable logistic regres-
sion models failed to establish associations between specimen
discordance and increased white blood cells on lavage,
immunosuppression and patients’ antimicrobial status. Patients
who were mechanically ventilated during bronchoscopy
appeared to have an increased risk of discordance (odds ratio
(OR), 2.12; 95% CI, 1.06–4.15), but upon adjusting for
increased number of microorganisms (≥3) per specimen in
multivariable analysis, the association was no longer observed.
PLEX-ID’s potential clinical impact in cases of discordant,
non-commensal specimens
Inter-rater reliability for the questions depicted in Fig. 1 was
slight to fair, with inter-rater agreement and kappa values
ranging from 29 to 50% and 0.036 to 0.308, respectively
(Table 4). Both reviewers found that in the majority of the 31
discordant, non-commensal cases, PLEX-ID results would have
TABLE 1. Baseline characteristics of patients and their BAL
specimens
Variable Data
Indications and diagnoses
Indication for BAL
LRTI suspected (%) 76/101 (75)
Routine pre- or post-transplant BAL (%) 12/101 (12)
Malignancy work-up (%) 5/101 (5)
Transplant rejection work-up (%) 4/101 (4)
Non-malignancy, non-infectious disease work-up (%) 4/101 (4)
Diagnosis post-BAL
No evidence of pulmonary infection (total, %) 59/101 (58)
Rejection (%) 4/59 (7)
Interstitial pneumopathy (%) 6/59 (10)
Cryptogenic organizing pneumonia (%) 2/59 (3)
ARDS (%) 1/59 (2)
Sarcoidosis (%) 1/59 (2)
Other (non-infectious diagnosis not assigned) 45/59 (76)
Pneumonia (total, %) 41/101 (41)
Bacterial 29/41 (71)
Pneumocystis jirovecii 4/41 (10)
Viral 3/41 (7)
Tuberculous 3/41 (7)
Fungal (non-pneumocystis) 2/41 (5)
Pulmonary abscess (total, %) 1/101 (1)
Quantitative specimen findings
Absolute number of organisms detected
By standard methods 172
By PLEX-ID 175
Combined 218
Distribution of all microorganisms detected
Bacterial (%) 182/218 (83)
Commensal oral flora 124/182 (68)
Fungal (%) 36/218 (17)
Moulds 10/36 (28)
Yeasts 26/36 (72)
Candida spp. 21/26 (81)
Number of distinct species identified
By standard methods 52
By PLEX-ID 46
Combined 56
Median number of organisms per specimen (range; IQR) 2 (0–7; 1–3)
Number of specimens yielding no organism (%) 9/101 (9)
Number of specimens yielding commensal oral flora (%) 69/92 (75)
Number of specimens yielding a fungus
(mould or yeast) (%)
31/92 (34)
Median number of white blood cells/mL (IQR)
Positive specimens with evaluable data (n = 75) 200 (120–345)
Negative specimens with evaluable data (n = 8) 145 (68–300)
ARDS, acute respiratory distress syndrome; BAL, bronchoalveolar lavage; IQR,
interquartile range; LRTI, lower respiratory tract infection.
TABLE 2. Concordance data between PLEX-ID and stan-
dard methods
Variable Data (%)
Concordance
Overall concordance 45/101 (45)
Concordance when excluding discordance for
commensal oral flora
67/101 (66)
Overall concordance among specimens from
patients diagnosed with pneumonia
post-bronchoscopy
12/41 (30)
Concordance among specimens from patients
diagnosed with pneumonia post-bronchoscopy,
excluding commensal flora
22/41 (54)
Discordance only at species level (genus identified
by both methods)
2/101 (2)
Undetected organisms and resistance
Among all organisms detected, number not
detected by PLEX-ID
43/218 (20)
Among all organisms detected, number not
detected by SM
46/218 (21)
Among all organisms detected by SM, the number
not detected by PLEX-ID
43/183 (24)
51/191 (26.7), p <0.001
Among all organisms detected by PLEX-ID, the
number not detected by SM
Among non-commensals detected by SM, number
not detected by PLEX-ID
24/68 (35)
26/70 (37), p <0.001Among non-commensals detected by PLEX-ID,
number not detected by SM
Among fungi detected by SM, number not detected
by PLEX-ID
6/21 (28.6)
15/30 (50), p 0.030Among fungi detected by PLEX-ID, number not
detected by SM
Organisms most often ‘missed’ by PLEX-ID, n (%)
Pneumocystis jirovecii 5/7 (71)
Actinomyces odontolyticus 4/18 (22)
Haemophilus influenzae 2/7 (29)
Escherichia coli 2/5 (40)
Organisms most often ‘missed’ by standard
methods, n (%)
Candida albicans 8/16 (50)
Streptococcus spp. 5/15 (33)
Streptococcus pneumoniae 5/6 (83)
Streptococcus group mitis (excluding S. pneumoniae) 3/22 (14)
‘Missed’ organisms, fungi, n (%)
PLEX-ID 6/36 (17)
SM 15/36 (42), p 0.030
mecA identification (%)a
PLEX-ID 7/7 (100)
SM 2/7 (29)
SM, standard methods.
aNo other resistance genes were identified throughout the study.
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had no impact at all, or probably no impact, on choice of
antimicrobial therapy within the 24 h following bronchoscopy,
as most patients were receiving broad-spectrum antimicrobials
empirically. In the majority of cases where reviewers did find
that PLEX-ID would probably or definitely have had an impact
on therapy, its impact would have been to allow for a
narrowing of the current antimicrobial spectrum (13/25, 52%).
Similarly, when asked whether PLEX-ID results would have
changed overall patient management, Reviewers 1 and 2
responded either not at all or probably not in 83% and 100% of
cases, respectively. In the few cases where PLEX-ID results
would have changed non-pharmacological management,
Reviewer 1 believed they would have led either to additional
microbiological testing or to other, non-interventional, diag-
nostic analyses such as biomarker testing.
Notably, PLEX-ID missed several clinically important patho-
gens on at least one occasion, among them Mycobacterium
tuberculosis, S. pneumoniae and Gram-negative rods such as
Chlamydophila pneumoniae, Escherichia coli, H. influenzae and
Morganella morganii.
Discussion
This prospective study documented a concordance of 45%
between PLEX-ID and standard diagnostic methods for
bacterial and fungal detection in BAL specimens. Among
patients with confirmed pneumonia post-bronchoscopy, over-
all specimen concordance was only 30%.
These results stand in contrast to those of earlier studies, in
which PLEX-ID was retrospectively compared with clearly
positive specimens other than BAL fluid. The version tested
seems to perform best in the detection of yeasts and, possibly,
resistance genes, though there were not enough samples
positive for either to confirm such a hypothesis here.
It may be argued that our study’s design hampered
PLEX-ID’s potential from the outset. PLEX-ID was tested as
a standalone diagnostic tool; as such it was not compared with
one alternative method but with a battery of techniques, many
of them already state-of-the-art.
Both the specimen type and the study population, which
included immunosuppressed patients, increased the probability
of discordance given their higher likelihood of polymicrobial
yields. Indeed, our specimens’ overall positivity rate was high
(91%), with up to seven microbes found per specimen. In
earlier studies, specimens issuing from more sterile body
compartments such as blood were tested; when positive, such
samples are only rarely polymicrobial [3]. When non-blood
tissue specimens were tested, these were controlled settings
in which PLEX-ID was tested retrospectively for the detection
of a single pathogen or pathogen type [5]. As noted above, the
tested version was designed to detect pathogens in sterile
fluids only. Appropriately, a PLEX-ID system including quan-
titative assays designed specifically for BAL and other
non-sterile fluids is currently under development.
TABLE 3. Species, genera or resistance genes identified by
standard methods and/or PLEX-ID in 41 specimens from
patients diagnosed with pneumonia after bronchoalveolar
lavage.Organisms in bold are considered commensal oral flora
Organism or
resistance gene
identified
Total number
of specimens
in which
identified
Number of
specimens in
which
identified
by SM
Number of
specimens in
which identified
by PLEX-ID
Actinomyces
odontolyticus
6 4 2
Aspergillus fumigatus 1 1 1
Bacillus cereus 1 1a 1
Candida albicans 7 2 7
Candida glabrata 1 1 1
Candida tropicalis 2 2 1
Chlamydophila
pneumoniae
1 1 0
Corynebacterium
propinquum
2 2 1
Corynebacterium
pseudodiphtheriticum
1 0 1
Cryptococcus spp. 1 0 1
Eikenella corrodens 1 0 1
Escherischia coli 3 3 2
Fusobacterium
nucleatum
1 1a 1
Gardnerella vaginalis 1 0 1
Gemella haemolysans 1 0 1
Gemella morbillorum 1 1a 1
Gemella sanguinis 2 2a 2
Granulicatella
adiacens
2 0 2
Haemophilus influenzae 3 3 3
Klebsiella pneumoniae 1 1 1
Lactobacillus gasseri 2 2a 2
Morganella morganii 1 1 0
Mycobacterium
tuberculosis
1 1 0
Mycoplasma pneumoniae 1 1 1
Neisseria meningitidis 1 1 1
Neisseria subflava 2 1a 2
Penicillium spp. 1 0 1
Pneumocystis jirovecii 5 5 2
Pseudomonas aeruginosa 7 5 6
Rhizomucor pusillus 3 3 3b
Rothia dentocariosa 1 1a 1
Rothia mucilaginosa 3 3a 3
Saccharomyces cerevisiae 2 1 2b
Staphylococcus aureus 2 2 2
S. aureus, methicillin-
sensitive
1 1 1
Staphylococcus
epidermidis
2 1 2
Streptococcus spp. 7 4 7
Streptococcus
anginosus group
1 1 1
Streptococcus
mitis group
(excluding Streptococcus
pneumoniae)
4 2a 4
S. pneumoniae 3 1 2
Streptococcus
pseudopneumoniae
1 1a 1
Streptococcus salivarius 1 1a 1
Streptococcus suis 1 1a 1
Streptococcus
thermophilus
1 0 1
Streptococcus viridans 1 0 1
mecA 4 1 4
aSM identified the organism at genus level only.
bIn one of the cases, PLEX-ID identified the organism at genus level only.
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The PLEX-ID platform was further at a disadvantage in that
fluid was first extracted from samples for SM analysis, and
often only a small—sometimes diluted—amount remained for
later PLEX-ID batch analysis. Indeed, the five instances of
missed P. jirovecii occurred in the setting of a prior supernatant
extraction for SM; in these cases, PLEX-ID did not actually
analyse the same sample volume that SM had.
Nonetheless, in light of these findings, PLEX-ID cannot
currently be recommended as a standalone diagnostic tool for
the detection of bacteria and fungi in BAL specimens. The results
of the clinical analysis would confirm as much. While in the
majority of cases, PLEX-ID results would not have had an impact
on antimicrobial therapy or other patient management, review-
ers worryingly commented in eight cases that PLEX-ID would
have led to ‘wrong decision-making’ with potential harm to
patients. Indeed, some of the microbes missed by PLEX-ID rank
among the most important and potentially lethal pathogens
producing human respiratory infections (M. tuberculosis,
S. pneumoniae, etc.). Of note, in most of the cases in which
PLEX-ID was considered likely to have an impact, that impact
would have been to enable clinicians to narrow the antimicrobial
spectrum more quickly.
Conclusions
PLEX-ID analysis of BAL specimens concurred weakly with
that of SM in the detection of bacteria and fungi. In its current
state, PLEX-ID may be useful as an adjunctive diagnostic tool in
situations where either slow cultivation would be required
(e.g. certain fungal pneumonias), or combined SM yield no
findings yet clinical suspicion remains high.
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